Signature Diagnostics

1 known investors

SignatureDx develops noninvasive diagnostics using cell-free DNA (cfDNA) from liquid biopsy to identify "signatures" for early prediction and detection of disease. Its research focuses on women's reproductive and maternal health, including pregnancy complications, and organ health such as kidney/lung monitoring and transplant rejection.